10 research outputs found
Recommended from our members
How IGF-II Binds to the Human Type 1 Insulin-like Growth Factor Receptor.
Human type 1 insulin-like growth factor receptor (IGF-1R) signals chiefly in response to the binding of insulin-like growth factor I. Relatively little is known about the role of insulin-like growth factor II signaling via IGF-1R, despite the affinity of insulin-like growth factor II for IGF-1R being within an order of magnitude of that of insulin-like growth factor I. Here, we describe the cryoelectron microscopy structure of insulin-like growth factor II bound to a leucine-zipper-stabilized IGF-1R ectodomain, determined in two conformations to a maximum average resolution of 3.2 Å. The two conformations differ in the relative separation of their respective points of membrane entry, and comparison with the structure of insulin-like growth factor I bound to IGF-1R reveals long-suspected differences in the way in which the critical C domain of the respective growth factors interact with IGF-1R
Understanding the mechanism of insulin and insulin-like growth factor (IGF) receptor activation by IGF-II
Extent: 9p.Background: Insulin-like growth factor-II (IGF-II) promotes cell proliferation and survival and plays an important role in normal fetal development and placental function. IGF-II binds both the insulin-like growth factor receptor (IGF-1R) and insulin receptor isoform A (IR-A) with high affinity. Interestingly both IGF-II and the IR-A are often upregulated in cancer and IGF-II acts via both receptors to promote cancer proliferation. There is relatively little known about the mechanism of ligand induced activation of the insulin (IR) and IGF-1R. The recently solved IR structure reveals a folded over dimer with two potential ligand binding pockets arising from residues on each receptor half. Site-directed mutagenesis has mapped receptor residues important for ligand binding to two separate sites within the ligand binding pocket and we have recently shown that the IGFs have two separate binding surfaces which interact with the receptor sites 1 and 2. Methodology/Principal Findings: In this study we describe a series of partial IGF-1R and IR agonists generated by mutating Glu12 of IGF-II. By comparing receptor binding affinities, abilities to induce negative cooperativity and potencies in receptor activation, we provide evidence that residue Glu12 bridges the two receptor halves leading to receptor activation. Conclusions/Significance: This study provides novel insight into the mechanism of receptor binding and activation by IGFII,which may be important for the future development of inhibitors of its action for the treatment of cancer.Clair L. Alvino, Shee Chee Ong, Kerrie A. McNeil, Carlie Delaine, Grant W. Booker, John C. Wallace and Briony E. Forbe
Insulin in motion: The A6-A11 disulfide bond allosterically modulates structural transitions required for insulin activity
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.The structural transitions required for insulin to activate its receptor and initiate regulation of glucose homeostasis are only partly understood. Here, using ring-closing metathesis, we substitute the A6-A11 disulfide bond of insulin with a rigid, non-reducible dicarba linkage, yielding two distinct stereo-isomers (cis and trans). Remarkably, only the cis isomer displays full insulin potency, rapidly lowering blood glucose in mice (even under insulin-resistant conditions). It also posseses reduced mitogenic activity in vitro. Further biophysical, crystallographic and molecular-dynamics analyses reveal that the A6-A11 bond configuration directly affects the conformational flexibility of insulin A-chain N-terminal helix, dictating insulin’s ability to engage its receptor. We reveal that in native insulin, contraction of the Cα-Cα distance of the flexible A6-A11 cystine allows the A-chain N-terminal helix to unwind to a conformation that allows receptor engagement. This motion is also permitted in the cis isomer, with its shorter Cα-Cα distance, but prevented in the extended trans analogue. These findings thus illuminate for the first time the allosteric role of the A6-A11 bond in mediating the transition of the hormone to an active conformation, significantly advancing our understanding of insulin action and opening up new avenues for the design of improved therapeutic analogues
How ligand binds to the type 1 insulin-like growth factor receptor
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
A Novel Approach to Identify Two Distinct Receptor Binding Surfaces of Insulin-like Growth Factor II*S⃞
Very little is known about the residues important for the interaction of
insulin-like growth factor II (IGF-II) with the type 1 IGF receptor (IGF-1R)
and the insulin receptor (IR). Insulin, to which IGF-II is homologous, is
proposed to cross-link opposite halves of the IR dimer through two receptor
binding surfaces, site 1 and site 2. In the present study we have analyzed the
contribution of IGF-II residues equivalent to insulin's two binding surfaces
toward the interaction of IGF-II with the IGF-1R and IR. Four “site
1” and six “site 2” analogues were produced and analyzed in
terms of IGF-1R and IR binding and activation. The results show that
Val43, Phe28, and Val14 (equivalent to site
1) are critical to IGF-1R and IR binding, whereas mutation to alanine of
Gln18 affects only IGF-1R and not IR binding. Alanine substitutions
at Glu12, Asp15, Phe19, Leu53, and
Glu57 analogues resulted in significant (>2-fold) decreases in
affinity for both the IGF-1R and IR. Furthermore, taking a novel approach
using a monomeric, single-chain minimized IGF-1R we have defined a distinct
second binding surface formed by Glu12, Phe19,
Leu53, and Glu57 that potentially engages the IGF-1R at
one or more of the FnIII domains
Probing the correlation between insulin activity and structural stability through introduction of the rigid A6–A11 bond
This research was originally published in the Journal of Biological Chemistry.
Ong, S. C., Belgi, A., van Lierop, B., Delaine, C., Andrikopoulos, S., MacRaild, C. A., … Forbes, B. E. Probing the correlation between insulin activity and structural stability through introduction of the rigid A6–A11 bond. J. Biol. Chem. 2018; V293, 11928-11943. © the Author(s).
which has been published in final form at
https://doi.org/10.1074/jbc.RA118.002486The development of fast-acting and highly stable insulin analogues is challenging. Insulin undergoes structural transitions essential for binding and activation of the insulin receptor (IR), but these conformational changes can also affect insulin stability. Previously, we substituted the insulin A6–A11 cystine with a rigid, non-reducible C=C linkage (“dicarba” linkage). A cis-alkene permitted the conformational flexibility of the A-chain N-terminal helix necessary for high-affinity IR binding, resulting in surprisingly rapid activity in vivo. Here, we show that, unlike the rapidly acting LysB28ProB29 insulin analogue (KP insulin), cis-dicarba insulin is not inherently monomeric. We also show that cis-dicarba KP insulin lowers blood glucose levels even more rapidly than KP insulin, suggesting that an inability to oligomerize is not responsible for the observed rapid activity onset of cis-dicarba analogues. Although rapid-acting, neither dicarba species is stable, as assessed by fibrillation and thermodynamics assays. MALDI analyses and molecular dynamics simulations of cis-dicarba insulin revealed a previously unidentified role of the A6–A11 linkage in insulin conformational dynamics. By controlling the conformational flexibility of the insulin B-chain helix, this linkage affects overall insulin structural stability. This effect is independent of its regulation of the A-chain N-terminal helix flexibility necessary for IR engagement. We conclude that high-affinity IR binding, rapid in vivo activity, and insulin stability can be regulated by the specific conformational arrangement of the A6–A11 linkage. This detailed understanding of insulin's structural dynamics may aid in the future design of rapid-acting insulin analogues with improved stability.SCO and BVL acknowledge the financial support from the Australian postgraduate scholarships.
RSN acknowledges fellowship support from the Australian National Health and Medical Research Council.
AJR and BEF acknowledge funding from the National Health and Medical Research Council (Project Grant APP1069328) and Australian Research Council (LP12020200792)
A structurally minimized yet fully active insulin based on cone-snail venom insulin principles
Human insulin and its current therapeutic analogs all show propensity, albeit varyingly, to self-associate into dimers and hexamers, which delays their onset of action and makes blood glucose management difficult for people with diabetes. Recently, we described a monomeric, insulin-like peptide in cone-snail venom with moderate human insulin-like bioactivity. Here, with insights from structural biology studies, we report the development of mini-Ins-a human des-octapeptide insulin analog-as a structurally minimal, full-potency insulin. Mini-Ins is monomeric and, despite the lack of the canonical B-chain C-terminal octapeptide, has similar receptor binding affinity to human insulin. Four mutations compensate for the lack of contacts normally made by the octapeptide. Mini-Ins also has similar in vitro insulin signaling and in vivo bioactivities to human insulin. The full bioactivity of mini-Ins demonstrates the dispensability of the PheB24-PheB25-TyrB26 aromatic triplet and opens a new direction for therapeutic insulin development
Alanine Scanning of a Putative Receptor Binding Surface of Insulin-like Growth Factor-I*
Current evidence supports a binding model in which the insulin molecule
contains two binding surfaces, site 1 and site 2, which contact the two halves
of the insulin receptor. The interaction of these two surfaces with the
insulin receptor results in a high affinity cross-linking of the two receptor
α subunits and leads to receptor activation. Evidence suggests that
insulin-like growth factor-I (IGF-I) may activate the IGF-I receptor in a
similar mode. So far IGF-I residues structurally corresponding to the residues
of the insulin site 1 together with residues in the C-domain of IGF-I have
been found to be important for binding of IGF-I to the IGF-I receptor
(e.g. Phe23, Tyr24, Tyr31,
Arg36, Arg37, Val44, Tyr60, and
Ala62). However, an IGF-I second binding surface similar to site 2
of insulin has not been identified yet. In this study, we have analyzed
whether IGF-I residues corresponding to the six residues of the insulin site 2
have a role in high affinity binding of IGF-I to the IGF-I receptor. Six
single-substituted IGF-I analogues were produced, each containing an alanine
substitution in one of the following positions (corresponding insulin residues
in parentheses): Glu9 (HisB10), Asp12
(GluB13), Phe16 (LeuB17), Asp53
(SerA12), Leu54 (LeuA13), and
Glu58 (GluA17). In addition, two analogues with 2 and 3
combined alanine substitutions were also produced (E9A,D12A IGF-I and
E9A,D12A,E58A IGF-I). The results show that introducing alanine in positions
Glu9, Asp12, Phe16, Leu54, and
Glu58 results in a significant reduction in IGF-I receptor binding
affinity, whereas alanine substitution at position 53 had no effect on IGF-I
receptor binding. The multiple substitutions resulted in a 33–100-fold
reduction in IGF-I receptor binding affinity. These data suggest that IGF-I,
in addition to the C-domain, uses surfaces similar to those of insulin in
contacting its cognate receptor, although the relative contribution of the
side chains of homologous residues varies
A novel binding site for the human insulin-like growth factor-II (IGF-II)/mannose 6-phosphate receptor on IGF-II
The mammalian insulin-like growth factor (IGF)-II/cation-independent mannose 6-phosphate receptor (IGF2R) binds IGF-II with high affinity. By targeting IGF-II to lysosomal degradation, it plays a role in the maintenance of correct IGF-II levels in the circulation and in target tissues. Loss of IGF2R function is associated with tumor progression; therefore, the IGF2R is often referred to as a tumor suppressor. The interaction between IGF2R and IGF-II involves domains 11 and 13 of the 15 extracellular domains of the receptor. Recently, a hydrophobic binding region was identified on domain 11 of the IGF2R. In contrast, relatively little is known about the residues of IGF-II that are involved in IGF2R binding and the determinants of IGF2R specificity for IGF-II over the structurally related IGF-I. Using a series of novel IGF-II analogues and surface plasmon resonance assays, this study revealed a novel binding surface on IGF-II critical for IGF2R binding. The hydrophobic residues Phe19 and Leu53 are critical for IGF2R binding, as are residues Thr16 and Asp52. Furthermore, Thr16 was identified as playing a major role in determining why IGF-II, but not IGF-I, binds with high affinity to the IGF2R.Carlie Delaine, Clair L. Alvino, Kerrie A. McNeil, Terrance D. Mulhern, Lisbeth Gauguin, Pierre De Meyts, E. Yvonne Jones, James Brown, John C. Wallace, and Briony E. Forbe
Structure and functional analysis of the IGF-II/IGF2R interaction
Embryonic development and normal growth require exquisite control of insulin-like growth factors (IGFs). In mammals the extracellular region of the cation-independent mannose-6-phosphate receptor has gained an IGF-II-binding function and is termed type II IGF receptor (IGF2R). IGF2R sequesters IGF-II; imbalances occur in cancers and IGF2R is implicated in tumour suppression. We report crystal structures of IGF2R domains 11–12, 11–12–13–14 and domains 11–12–13/IGF-II complex. A distinctive juxtaposition of these domains provides the IGF-II-binding unit, with domain 11 directly interacting with IGF-II and domain 13 modulating binding site flexibility. Our complex shows that Phe19 and Leu53 of IGF-II lock into a hydrophobic pocket unique to domain 11 of mammalian IGF2Rs. Mutagenesis analyses confirm this IGF-II ‘binding-hotspot', revealing that IGF-binding proteins and IGF2R have converged on the same high-affinity site